Celgene

File:Celgene logo.svg

Celgene logo

Celgene Corporation was an American biotechnology company that discovered, developed, and commercialized medicines for cancer and inflammatory disorders. It was founded in 1986 and became one of the leading companies in the biopharmaceutical industry. Celgene's headquarters were located in Summit, New Jersey, United States. The company's major products included Revlimid (lenalidomide), for the treatment of multiple myeloma and other blood cancers; Pomalyst/Imnovid (pomalidomide), also for multiple myeloma; and Otezla (apremilast), for the treatment of psoriatic arthritis and psoriasis. In addition to its marketed products, Celgene had a robust pipeline of investigational drugs and was involved in numerous collaborations with other biotechnology and pharmaceutical companies.

History

Celgene was initially a unit of Celanese Corporation before it was spun off as an independent company. Over the years, Celgene grew through a combination of organic growth, acquisitions, and partnerships. Notably, it acquired several companies that expanded its portfolio of cancer and inflammatory disease treatments. Celgene's strategy focused on targeting high unmet medical needs, investing heavily in research and development to bring new therapies to market.

In 2019, Celgene was acquired by Bristol-Myers Squibb (BMS) in a deal valued at approximately $74 billion. The acquisition aimed to create a leading biopharma company with a strong focus on cancer, cardiovascular diseases, immunology, and fibrosis. Following the acquisition, Celgene's products and pipeline became part of BMS's portfolio.

Products and Research

Celgene's success was largely driven by its flagship product, Revlimid, which became a blockbuster drug in the treatment of multiple myeloma. Revlimid works by modulating the immune system and inhibiting cancer cell growth. Celgene's other products, such as Pomalyst and Otezla, also contributed significantly to the company's revenue and expanded its presence in the oncology and inflammatory disease markets.

The company's research and development efforts were focused on discovering new therapies and improving existing treatments. Celgene was known for its innovative approach to drug development, including the use of novel drug delivery systems and targeting mechanisms. Its pipeline included candidates for a variety of diseases, with a particular emphasis on hematology and oncology.

Acquisitions and Partnerships

Throughout its history, Celgene engaged in strategic acquisitions and partnerships to enhance its product portfolio and research capabilities. These moves allowed Celgene to access new technologies and expand its therapeutic areas. Some of the companies acquired by Celgene included Abraxis BioScience, Pharmion, and Juno Therapeutics. These acquisitions brought in new products and bolstered Celgene's position in the biopharmaceutical sector.

Regulatory Challenges

Like many biopharmaceutical companies, Celgene faced regulatory challenges, including scrutiny over drug pricing and approval processes. The company worked closely with regulatory agencies worldwide to ensure compliance and address any concerns related to its products and practices.

Legacy

Celgene's legacy in the biopharmaceutical industry is marked by its commitment to innovation and patient care. The company's products have made significant contributions to the treatment of cancer and inflammatory diseases, improving the lives of patients around the world. Following its acquisition by Bristol-Myers Squibb, Celgene's mission and values continue to influence the combined company's approach to drug development and healthcare solutions.

This article is a stub You can help WikiMD by registering and expanding it with useful details, internal links, formatting, and categories. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health and wellness encyclopedia.